Bambusa Therapeutics priced its upsized initial public offering at $16 per share for 10,555,555 common shares, generating expected gross proceeds of $168,888,880 before underwriting discounts, commissions and other offering expenses. The company granted underwriters a 30-day option to buy up to 1,583,333 additional shares at the IPO price, less applicable discounts and commissions. Bambusa expects its stock to begin trading on the Nasdaq Global Select Market on October 30, 2026, under the ticker BBTX, with the offering expected to close on November 2, subject to customary conditions. BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are joint book-running managers. Bambusa is developing long-acting precision bispecific antibodies (drugs designed to bind two biological targets) for immunology and inflammation, including clinical programs BBT001 and BBT002 and preclinical programs BBT003 and BBT004. The company said its forward-looking statements, including those covering trading, the offering close, development plans and product-candidate advantages, are subject to risks and uncertainties.